



## **Quanta to Exhibit at the 55<sup>th</sup> Annual ERA-EDTA Congress**

**Alcester, Warwickshire, UK, 21 May 2018:** Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces that the Company will be exhibiting at the 55<sup>th</sup> Annual European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress which runs from Thursday 24<sup>th</sup> to Sunday 27<sup>th</sup> May, at the Bella Center in Copenhagen, Denmark, at booth number 4.151.

Quanta will be showcasing its new look, state-of-the-art personal haemodialysis system, SC+, designed to offer patients flexibility enabling them to fit treatment around everyday life.

Quanta will also present a poster at the congress which will conclude the results of the SC+ Pilot Study, which includes extensive, successful, patient treatments at four NHS Trusts across the UK.

Full details of the poster are as follows:

**Date:** 26 May 2018  
**Time:** 09:30 – 10:45 and 16:30 – 17:00  
**Number:** SP474  
**Title:** Implementation of a compact haemodialysis system in a real-world environment: assessment of user uptake, safety, performance and usability.  
**Authors:** Dr. Charlotte Bebb, Dr. Clara Day, Dr. Cormac Breen, Dr. Sandip Mitra, John E. Milad and James Grainger

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer or Peter Hoyer, Chief Commercial Officer, at the conference, please contact [enquiries@quantadt.com](mailto:enquiries@quantadt.com).

ERA-EDTA brings together worldwide physicians and kidney specialists to learn and share the latest advances in the field of clinical nephrology, dialysis, renal transplantation and related subjects.

**-ENDS-**

**For more information about Quanta, please contact:**

**Quanta**

John E. Milad,  
Chief Executive Officer

T: +44 (0)1789 400043

E: [enquiries@quantadt.com](mailto:enquiries@quantadt.com)

**Consilium Strategic Communications**

Amber Fennell / Matthew Neal / Lindsey Neville

T: +44 (0)203 709 5708

E: [quanta@consilium-comms.com](mailto:quanta@consilium-comms.com)

**About SC+**

SC+ is a unique small, simple and powerful haemodialysis system that supports patients across the continuum of care, from the clinic to the home. SC+ provides clinical efficacy and high flow rates compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users across a wide range of settings.

**About Quanta**

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta's lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Stage Capital (formerly NBGI Ventures), Wellington Partners, Seroba Life Sciences, b-to-v Partners, ALIAD, CITA, Seventure Partners and Kuwait Life Sciences Company, as well as founding partner IMI plc.

For more information, please visit: [www.quantadt.com](http://www.quantadt.com).